Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016092472> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W2016092472 abstract "Angiogenesis, formation of new vasculature, is critical to cancer growth. Agents that block angiogenesis, in particular bevacizumab, a monoclonal antibody that binds vascular endothelial growth factor, the key ligand in angiogenesis, have become an important option for many patients with non-small cell lung cancer (NSCLC). Activity was first demonstrated in Eastern Cooperative Oncology Group E4599, a large phase 3 trial that randomized patients with newly diagnosed, nonsquamous NSCLC to receive carboplatin/paclitaxel with or without bevacizumab at 15 mg/kg every 3 weeks. The study demonstrated significant improvements in response rate, progression-free survival, and overall survival with the addition of bevacizumab. Median overall survival improved from 10.3 to 12.3 months (p = 0.003). Significant toxic effects, including fatal hemoptysis, however, resulted in 15 treatment-related deaths in the bevacizumab arm. The beneficial results were recently confirmed in the European Avastin in Lung Cancer B017704 (AVAiL) trial. In AVAiL, patients with newly diagnosed nonsquamous NSCLC were randomized to receive cisplatin/gemcitabine with or without bevacizumab at doses of either 7.5 or 15 mg/kg every 3 weeks. Both doses resulted in statistically significant improvements in response rate and progression-free survival, but overall survival results have yet to be presented. Based on these encouraging results, the drug is now being studied in earlier-stage disease as neoadjuvant or adjuvant therapy and in locally advanced NSCLC. Exploration of the safety and efficacy of the drug in combination with other chemotherapeutics and targeted agents, and in previously excluded patient populations such as those with brain metastases, is also ongoing." @default.
- W2016092472 created "2016-06-24" @default.
- W2016092472 creator A5035640724 @default.
- W2016092472 date "2008-06-01" @default.
- W2016092472 modified "2023-09-28" @default.
- W2016092472 title "Antibodies to Vascular Endothelial Growth Factor in Non-small Cell Lung Cancer" @default.
- W2016092472 cites W129944274 @default.
- W2016092472 cites W1969328947 @default.
- W2016092472 cites W1978139448 @default.
- W2016092472 cites W1980725734 @default.
- W2016092472 cites W1985712533 @default.
- W2016092472 cites W1999759354 @default.
- W2016092472 cites W2010706089 @default.
- W2016092472 cites W2100785570 @default.
- W2016092472 cites W2108969509 @default.
- W2016092472 cites W2109154917 @default.
- W2016092472 cites W2110610232 @default.
- W2016092472 cites W2126310082 @default.
- W2016092472 cites W2137009016 @default.
- W2016092472 cites W2141114204 @default.
- W2016092472 cites W2145835533 @default.
- W2016092472 cites W2153991063 @default.
- W2016092472 cites W2154200023 @default.
- W2016092472 cites W2157769714 @default.
- W2016092472 cites W2170198208 @default.
- W2016092472 cites W2170655985 @default.
- W2016092472 cites W2245767173 @default.
- W2016092472 cites W2287692022 @default.
- W2016092472 cites W2338895227 @default.
- W2016092472 cites W2470588482 @default.
- W2016092472 cites W2595221417 @default.
- W2016092472 doi "https://doi.org/10.1097/jto.0b013e318174e993" @default.
- W2016092472 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18520292" @default.
- W2016092472 hasPublicationYear "2008" @default.
- W2016092472 type Work @default.
- W2016092472 sameAs 2016092472 @default.
- W2016092472 citedByCount "18" @default.
- W2016092472 countsByYear W20160924722012 @default.
- W2016092472 countsByYear W20160924722013 @default.
- W2016092472 countsByYear W20160924722015 @default.
- W2016092472 countsByYear W20160924722019 @default.
- W2016092472 crossrefType "journal-article" @default.
- W2016092472 hasAuthorship W2016092472A5035640724 @default.
- W2016092472 hasBestOaLocation W20160924721 @default.
- W2016092472 hasConcept C126322002 @default.
- W2016092472 hasConcept C143998085 @default.
- W2016092472 hasConcept C167734588 @default.
- W2016092472 hasConcept C2776256026 @default.
- W2016092472 hasConcept C2776694085 @default.
- W2016092472 hasConcept C2777025900 @default.
- W2016092472 hasConcept C2777292972 @default.
- W2016092472 hasConcept C2777802072 @default.
- W2016092472 hasConcept C2778239845 @default.
- W2016092472 hasConcept C2780258809 @default.
- W2016092472 hasConcept C2780394083 @default.
- W2016092472 hasConcept C2781451048 @default.
- W2016092472 hasConcept C71924100 @default.
- W2016092472 hasConceptScore W2016092472C126322002 @default.
- W2016092472 hasConceptScore W2016092472C143998085 @default.
- W2016092472 hasConceptScore W2016092472C167734588 @default.
- W2016092472 hasConceptScore W2016092472C2776256026 @default.
- W2016092472 hasConceptScore W2016092472C2776694085 @default.
- W2016092472 hasConceptScore W2016092472C2777025900 @default.
- W2016092472 hasConceptScore W2016092472C2777292972 @default.
- W2016092472 hasConceptScore W2016092472C2777802072 @default.
- W2016092472 hasConceptScore W2016092472C2778239845 @default.
- W2016092472 hasConceptScore W2016092472C2780258809 @default.
- W2016092472 hasConceptScore W2016092472C2780394083 @default.
- W2016092472 hasConceptScore W2016092472C2781451048 @default.
- W2016092472 hasConceptScore W2016092472C71924100 @default.
- W2016092472 hasLocation W20160924721 @default.
- W2016092472 hasLocation W20160924722 @default.
- W2016092472 hasOpenAccess W2016092472 @default.
- W2016092472 hasPrimaryLocation W20160924721 @default.
- W2016092472 hasRelatedWork W2144660856 @default.
- W2016092472 hasRelatedWork W2145835533 @default.
- W2016092472 hasRelatedWork W2162724777 @default.
- W2016092472 isParatext "false" @default.
- W2016092472 isRetracted "false" @default.
- W2016092472 magId "2016092472" @default.
- W2016092472 workType "article" @default.